174 related articles for article (PubMed ID: 28755052)
1. USP Apparatus 4: a Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds.
Forrest WP; Reuter KG; Shah V; Kazakevich I; Heslinga M; Dudhat S; Patel S; Neri C; Mao Y
AAPS PharmSciTech; 2018 Jan; 19(1):413-424. PubMed ID: 28755052
[TBL] [Abstract][Full Text] [Related]
2. Interpreting
Rudd ND; Reibarkh M; Fang R; Mittal S; Walsh PL; Brunskill APJ; Forrest WP
Mol Pharm; 2020 May; 17(5):1734-1747. PubMed ID: 32267708
[TBL] [Abstract][Full Text] [Related]
3. Probing in Vitro Release Kinetics of Long-Acting Injectable Nanosuspensions via Flow-NMR Spectroscopy.
Rudd ND; Helmy R; Dormer PG; Williamson RT; Wuelfing WP; Walsh PL; Reibarkh M; Forrest WP
Mol Pharm; 2020 Feb; 17(2):530-540. PubMed ID: 31895571
[TBL] [Abstract][Full Text] [Related]
4. Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome.
Tang J; Srinivasan S; Yuan W; Ming R; Liu Y; Dai Z; Noble CO; Hayes ME; Zheng N; Jiang W; Szoka FC; Schwendeman A
Eur J Pharm Biopharm; 2019 Jan; 134():107-116. PubMed ID: 30481559
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
Kocbek P; Baumgartner S; Kristl J
Int J Pharm; 2006 Apr; 312(1-2):179-86. PubMed ID: 16469459
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations.
Fotaki N; Aivaliotis A; Butler J; Dressman J; Fischbach M; Hempenstall J; Klein S; Reppas C
Eur J Pharm Biopharm; 2009 Sep; 73(1):115-20. PubMed ID: 19442728
[TBL] [Abstract][Full Text] [Related]
7. Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluation.
Yadav SK; Mishra S; Mishra B
AAPS PharmSciTech; 2012 Dec; 13(4):1031-44. PubMed ID: 22893314
[TBL] [Abstract][Full Text] [Related]
8. A novel USP apparatus 4 based release testing method for dispersed systems.
Bhardwaj U; Burgess DJ
Int J Pharm; 2010 Mar; 388(1-2):287-94. PubMed ID: 20083176
[TBL] [Abstract][Full Text] [Related]
9. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
[TBL] [Abstract][Full Text] [Related]
10. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
[TBL] [Abstract][Full Text] [Related]
11. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
[TBL] [Abstract][Full Text] [Related]
12. Accelerated in vitro release testing method for naltrexone loaded PLGA microspheres.
Andhariya JV; Choi S; Wang Y; Zou Y; Burgess DJ; Shen J
Int J Pharm; 2017 Mar; 520(1-2):79-85. PubMed ID: 28153651
[TBL] [Abstract][Full Text] [Related]
13. Application of spray granulation for conversion of a nanosuspension into a dry powder form.
Bose S; Schenck D; Ghosh I; Hollywood A; Maulit E; Ruegger C
Eur J Pharm Sci; 2012 Aug; 47(1):35-43. PubMed ID: 22565066
[TBL] [Abstract][Full Text] [Related]
14. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
Tajiri T; Morita S; Sakamoto R; Mimura H; Ozaki Y; Reppas C; Kitamura S
Int J Pharm; 2015 Jul; 490(1-2):368-74. PubMed ID: 26022889
[TBL] [Abstract][Full Text] [Related]
15. Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50.
Jantratid E; Janssen N; Chokshi H; Tang K; Dressman JB
Eur J Pharm Biopharm; 2008 Jun; 69(2):776-85. PubMed ID: 18226882
[TBL] [Abstract][Full Text] [Related]
16. Nanosuspension formulations of poorly water-soluble compounds for intravenous administration in exploratory toxicity studies: in vitro and in vivo evaluation.
Fujimura H; Komasaka T; Tomari T; Kitano Y; Takekawa K
J Appl Toxicol; 2016 Oct; 36(10):1259-67. PubMed ID: 26849104
[TBL] [Abstract][Full Text] [Related]
17. In vitro release testing method development for long-acting injectable suspensions.
Bao Q; Wang X; Zou Y; Wang Y; Burgess DJ
Int J Pharm; 2022 Jun; 622():121840. PubMed ID: 35595043
[TBL] [Abstract][Full Text] [Related]
18. Formulation parameters of crystalline nanosuspensions on spray drying processing: a DoE approach.
Kumar S; Xu X; Gokhale R; Burgess DJ
Int J Pharm; 2014 Apr; 464(1-2):34-45. PubMed ID: 24447788
[TBL] [Abstract][Full Text] [Related]
19. Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs.
Wang Y; Miao X; Sun L; Song J; Bi C; Yang X; Zheng Y
Curr Pharm Des; 2014; 20(3):454-73. PubMed ID: 23651402
[TBL] [Abstract][Full Text] [Related]
20. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
